



NDA 19-851/S-028

Novartis Pharmaceuticals Corporation
Attention: Mr. Carl Schlotfeldt
One Health Plaza
East Hanover, New Jersey 07936-1080

Dear Mr. Schlotfeldt:

Please refer to your supplemental new drug application dated April 25, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lotensin (benazepril HCl) 5, 10, 20 and 40 mg Tablets.

We acknowledge receipt of your submission dated December 15, 2003.

Your submission dated December 15, 2003 constituted a complete response to our October 24, 2003 action letter.

This supplemental new drug application proposes changes in the **DESCRIPTION, CLINICAL PHARMACOLOGY, PRECAUTIONS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION** sections of the labeling concerning the use of Lotensin (benazepril HCl) 5, 10, 20 and 40 mg Tablets in pediatric patients with hypertension.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling submitted on April 25, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-851/S-028." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call:

Alisea Sermon, Pharm.D.
Regulatory Project Manager
(301) 594-5334

Sincerely,

{See appended electronic signature page}

Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Doug Throckmorton
3/2/04 10:44:43 AM